Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

Eli Lilly’s Weight Loss Pill Doesn’t Work as Well as Investors Hoped. The Obesity Trade Is Wavering Again. Eli Lilly’s weight ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

“The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...

Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...